DOI: 10.5281/zenodo.8403031
title: Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition

description: Data-Sets of, “Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition” The Dataset (Derived from https://doi.org/10.1111/bph.16251) contains the original figures and tables as PNG-format (10.1111_bph.16251_Figure 1-4.PNG; 10.1111_bph.16251_Table1-2.PNG and supplemental information 10.1111_bph.16251_FigS1-S2.PNG; 10.1111_bph.16251_TableS1-S6.PNG), as well as the graphical abstract.PNG Corresponding raw data and subsequent data analysis obtained from LC-MS/MS analysis and reused data on THF, THE and allo-THE and clinical parameters as well as the statistical evaluation of obtained data are provided as raw-files and corresponding meta data-files (FAIR-Principle). Fig 2: Two files in CSV format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_3.csv and 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_1.csv). Detailed description of the LC-MS/MS method is provided as pdf-Format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_M_2.pdf). All further experiment related information provided as one meta-data-file (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_3_M .txt) in txt format and two files containing further related information (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_M_A1-2 .pdf) PDF format. Fig3: Two files in CSV format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_4.csv; 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_2.csv). One meta data file as pdf-format with detailed LC-MS/MS method description 310030-(214978_10.1111_bph.16251_CGC_Human_Biomarker_4_M_2.pdf). All further related information are provided as one meta-data-file (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_4_M .txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_M_B1-3). Fig 4: Six files in CSV format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_3-5 .csv, 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_1.csv and 214978_10.1111_bph.16251_CGC_Human_Biomarker_28_1-2.csv). Two meta data file as pdf-format with detailed LC-MS/MS method descriptions (214978_10.1111_bph.16251_CGC_Human_Biomarker_4_M_2-3 .pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_3-5_M.txt) in txt format. Cohort related information is provided as five files in pdf- format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_M_A1-2 and B1-3.pdf) Statistical analysis is provided as R-File (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_M_1_1.R). Tab1: One file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_1 .csv). One meta file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_1.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_1_M.txt) in txt format. Cohort A related information is provided as two files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2). Tab2: One file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_2.csv). One meta data file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_1.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_2_M.txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_B1-3). Fig S1: Four files in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_3-4.csv and 214978_10.1111_BPH.16251_CGC_Human_Biomarker_28_1-2.csv). One meta data file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_3-4_M.txt) in txt format. Cohort A and B related information is provided as five files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2 and-B1-3). Fig S2: Five files in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_3-4.csv and 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_2.csv, 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_1-2.csv) and one file as R-File (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_2_M1.R). One meta data file as pdf-format provides detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2.pdf). All further related information are provided as one meta-data-file (310030 214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_26_2_M.txt) in txt format. Cohort A and B related information is provided as five files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2 and-B1-3). Tab S1: One file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_28_3.csv). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_28_3_M.txt) in txt format. Cohort A related information is provided as two files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2). TabS2: One file in CSV format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_4.csv). All further related information are provided as one meta-data-file (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_4_M.txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_M_B1-3). TabS3: One file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_3.csv). Detailed description of the LC-MS/MS method is provided as pdf-Formate (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2.pdf) All further experiment related information provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_3_M.txt) in txt format and two files containing further related information (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2 .pdf) PDF format. Tab S4: Three file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_5.csv, 310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_1-2.csv). Detailed description of the LC-MS/MS methods is provided two files pdf-Format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2-3.pdf) All further experiment related information provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_4_M.txt) in txt format. Cohort related information is provided as two files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2. Statistical analysis is provided as R-File (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_M_1.R). TabS5: One files in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_4.csv One meta data file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_5_M.txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_B1-3). TabS6: Four files in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_4-5.csv 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_4.csv; 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_1.csv). One meta data file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2-3.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_6_M.txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_B1-3).
description: Conclusion and Implications:11β-HSD1inhibition does not cause major alterations in bile acid homeostasis.The GUDCA/G7oxoLCA ratio represents the first blood biomarker of pharmacological 11β-HSD1inhibition and may replace or complement the urinary (5αTHF+THF)/THE ratio biomarker.